1;Preface;5 2;1 Plenary Articles;19 2.1;1.1 Proteomics strategies targeting biomarkers for cardiovascular disease;21 2.2;1.2 Influence of pre-examination aspects on result's validity - are ISO 15189 requirements sufficient and clear?;27 2.3;1.3 Posttranslational modifications in tumor diagnosis;30 2.4;1.4 Chronic inflammatory disease: a result of complex gene-environment interaction;34 3;2 Symposium Articles;39 3.1;2.1 Component-array technology diagnostics: a step forward in the study of the sensitization profile of allergic patients;41 3.2;2.2 Pediatric metabolic syndrome: pathophysiology and molecular mechanisms;44 3.3;2.3 Urinary 8-hydroxydeoxyguanosine as a biomarker of microangiopathic complications in type 2 diabetic patients;48 3.4;2.4 Biological variation data: the need for appraisal of the evidence base;53 3.5;2.5 RecoveryELISA - a newly developed immunoassay for measurement of therapeutic antibodies and the target antigen during antibody therapy;56 3.6;2.6 Genotypic prediction of HIV-1 tropism from plasma and peripheral blood mononuclear cells in the clinical routine laboratory;60 3.7;2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size;64 3.8;2.8 Serological markers of gastric pathology;68 3.9;2.9 BNP as a biomarker of cardiac impairment in neonates with congenital heart diseases;72 3.10;2.10 Are 25-hydroxyvitamin D assays fit for purpose?;76 3.11;2.11 Update on multiple sclerosis;79 3.12;2.12 Microalbuminuria and urinary retinol binding protein as markers of subtle renal injury in visceral leishmaniasis: sensitivity, specificity and predictive values of the immunoturbidimetric technique;83 3.13;2.13 Occult hepatitis B virus infection: diagnosis and significance;86 3.14;2.14 Unmet needs in chronic kidney disease testing;90 3.15;2.15 Towards a national chronic kidney disease testing program;93 3.16;2.16 Biochemistry and metabolism of vitamin D;96 3.17;2.17 Diagnostics of thalassemia;100 3.18;2.18 The specific roles of assessors during accreditation;103 3.19;2.19 Laboratory diagnosis of hereditary spherocytosis;106 3.20;2.20 Quantification of blood folate forms using stable-isotope dilution ultra performance liquid chromatography tandem mass spectrometry;109 3.21;2.21 Evaluation of the new Marburg cerebrospinal fluid model with human spondylopathies;113 3.22;2.22 E-learning experiences of national societies of clinical chemistry and laboratory medicine;117 3.23;2.23 The experience of Médecins Sans Frontières in laboratory medicine in resource-limited settings;120 3.24;2.24 Screening, identifying, and quantifying small molecules by hyphenated mass spectrometry in toxicology and drug monitoring - an update;126 3.25;2.25 Analytical quality in the Latin America area;129 3.26;2.26 Standardization in molecular diagnostics: definitions and uses of nucleic acid reference materials;134 3.27;2.27 Profiling of antiphospolipid antibodies - association with cerebrovascular events in APS;138 3.28;2.28 Plasma levels of soluble CD30 and CD40L in pediatric patients after liver transplantation;142 3.29;2.29 Diagnostic and prognostic value of presepsin (soluble CD14 subtype) in emergency patients with early sepsis using the new assay PATHFAST presepsin;146 3.30;2.30 Diagnostic workup of primary aldosteronism;152 3.31;2.31 What should the clinical laboratory and the toxicologist-pharmacologist offer the poisoned patient?;156 3.32;2.32 Novel aspects of von Willebrand factor - platelet glycoprotein IB interaction and signaling;160 3.33;2.33 Medical emergencies: what is the laboratory's role?;161